Shearman & Sterling is advising Novartis on its proposed $3.9 billion acquisition of Nasdaq-listed Advanced Accelerator Applications, a radiopharmaceutical company that develops, produces and commercializes Molecular Nuclear Medicines. The transaction will strengthen Novartis' oncology presence with both near-term product launches as well as a new technology platform with potential applications across a number of oncology early development programs.
Novartis provides innovative healthcare solutions and offers a diversified portfolio of innovative medicines, cost-saving generic and biosimilar pharmaceuticals and eye care. Novartis products are sold in approximately 155 countries around the world. The integration of Advanced Accelerator Applications with Novartis would build on Novartis' expertise in diseases associated with neuroendocrine tumors and introduce a new technology platform to Novartis providing an innovative approach to treating cancer.